130 related articles for article (PubMed ID: 21757252)
1. The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine.
Kao SC; Harvie R; Paturi F; Taylor R; Davey R; Abraham R; Clarke S; Marx G; Cullen M; Kerestes Z; Pavlakis N
Lung Cancer; 2012 Feb; 75(2):248-54. PubMed ID: 21757252
[TBL] [Abstract][Full Text] [Related]
2. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
Kindler HL; Karrison TG; Gandara DR; Lu C; Krug LM; Stevenson JP; Jänne PA; Quinn DI; Koczywas MN; Brahmer JR; Albain KS; Taber DA; Armato SG; Vogelzang NJ; Chen HX; Stadler WM; Vokes EE
J Clin Oncol; 2012 Jul; 30(20):2509-15. PubMed ID: 22665541
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
Byrne MJ; Davidson JA; Musk AW; Dewar J; van Hazel G; Buck M; de Klerk NH; Robinson BW
J Clin Oncol; 1999 Jan; 17(1):25-30. PubMed ID: 10458214
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma.
Kovac V; Zwitter M; Rajer M; Marin A; Debeljak A; Smrdel U; Vrankar M
Anticancer Drugs; 2012 Feb; 23(2):230-8. PubMed ID: 22027538
[TBL] [Abstract][Full Text] [Related]
5. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma.
Nowak AK; Byrne MJ; Williamson R; Ryan G; Segal A; Fielding D; Mitchell P; Musk AW; Robinson BW
Br J Cancer; 2002 Aug; 87(5):491-6. PubMed ID: 12189542
[TBL] [Abstract][Full Text] [Related]
6. PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.
Vogel A; Kasper S; Bitzer M; Block A; Sinn M; Schulze-Bergkamen H; Moehler M; Pfarr N; Endris V; Goeppert B; Merx K; Schnoy E; Siveke JT; Michl P; Waldschmidt D; Kuhlmann J; Geissler M; Kahl C; Evenkamp R; Schmidt T; Kuhlmann A; Weichert W; Kubicka S
Eur J Cancer; 2018 Mar; 92():11-19. PubMed ID: 29413685
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).
Kalmadi SR; Rankin C; Kraut MJ; Jacobs AD; Petrylak DP; Adelstein DJ; Keohan ML; Taub RN; Borden EC
Lung Cancer; 2008 May; 60(2):259-63. PubMed ID: 18006112
[TBL] [Abstract][Full Text] [Related]
8. Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.
Shukuya T; Takahashi T; Imai H; Tokito T; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Murakami H; Endo M; Yamamoto N
Respir Investig; 2014 Mar; 52(2):101-6. PubMed ID: 24636265
[TBL] [Abstract][Full Text] [Related]
9. Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.
Young RJ; Tin AW; Brown NJ; Jitlal M; Lee SM; Woll PJ
Br J Cancer; 2012 Mar; 106(6):1153-9. PubMed ID: 22353811
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
Buikhuisen WA; Burgers JA; Vincent AD; Korse CM; van Klaveren RJ; Schramel FM; Pavlakis N; Nowak AK; Custers FL; Schouwink JH; Gans SJ; Groen HJ; Strankinga WF; Baas P
Lancet Oncol; 2013 May; 14(6):543-51. PubMed ID: 23583604
[TBL] [Abstract][Full Text] [Related]
11. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma.
van Haarst JM; Baas P; Manegold Ch; Schouwink JH; Burgers JA; de Bruin HG; Mooi WJ; van Klaveren RJ; de Jonge MJ; van Meerbeeck JP
Br J Cancer; 2002 Feb; 86(3):342-5. PubMed ID: 11875695
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study.
Castagneto B; Zai S; Dongiovanni D; Muzio A; Bretti S; Numico G; Botta M; Sinaccio G
Am J Clin Oncol; 2005 Jun; 28(3):223-6. PubMed ID: 15923792
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma.
Arrieta O; López-Macías D; Mendoza-García VO; Bacon-Fonseca L; Muñoz-Montaño W; Macedo-Pérez EO; Muñiz-Hernández S; Blake-Cerda M; Corona-Cruz JF
Cancer Chemother Pharmacol; 2014 May; 73(5):975-82. PubMed ID: 24687408
[TBL] [Abstract][Full Text] [Related]
14. The role of gemcitabine in the treatment of malignant mesothelioma.
Kindler HL; van Meerbeeck JP
Semin Oncol; 2002 Feb; 29(1):70-6. PubMed ID: 11836671
[TBL] [Abstract][Full Text] [Related]
15. Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma.
Utkan G; Büyükçelik A; Yalçin B; Akbulut H; Demirkazik A; Dinçol D; Onur H; Gören D; Mousa U; Senler FC; Içli F
Lung Cancer; 2006 Sep; 53(3):367-74. PubMed ID: 16828196
[TBL] [Abstract][Full Text] [Related]
16. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia.
Lee CW; Murray N; Anderson H; Rao SC; Bishop W
Lung Cancer; 2009 Jun; 64(3):308-13. PubMed ID: 19004520
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.
Colucci G; Labianca R; Di Costanzo F; Gebbia V; Cartenì G; Massidda B; Dapretto E; Manzione L; Piazza E; Sannicolò M; Ciaparrone M; Cavanna L; Giuliani F; Maiello E; Testa A; Pederzoli P; Falconi M; Gallo C; Di Maio M; Perrone F; ; ;
J Clin Oncol; 2010 Apr; 28(10):1645-51. PubMed ID: 20194854
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
Colucci G; Giuliani F; Gebbia V; Biglietto M; Rabitti P; Uomo G; Cigolari S; Testa A; Maiello E; Lopez M
Cancer; 2002 Feb; 94(4):902-10. PubMed ID: 11920457
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.
Heinemann V; Quietzsch D; Gieseler F; Gonnermann M; Schönekäs H; Rost A; Neuhaus H; Haag C; Clemens M; Heinrich B; Vehling-Kaiser U; Fuchs M; Fleckenstein D; Gesierich W; Uthgenannt D; Einsele H; Holstege A; Hinke A; Schalhorn A; Wilkowski R
J Clin Oncol; 2006 Aug; 24(24):3946-52. PubMed ID: 16921047
[TBL] [Abstract][Full Text] [Related]
20. Rapid decrease in serum VEGF-A levels may be a worse prognostic biomarker for patients with platinum-resistant recurrent ovarian cancer treated with bevacizumab and gemcitabine.
Soyama H; Miyamoto M; Matsuura H; Iwahashi H; Kakimoto S; Ishibashi H; Sakamoto T; Hada T; Suminokura J; Takano M
Cancer Chemother Pharmacol; 2020 May; 85(5):941-947. PubMed ID: 32279102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
